RTW Investments LP Has $112.95 Million Stake in Masimo Co. (NASDAQ:MASI)

RTW Investments LP decreased its holdings in Masimo Co. (NASDAQ:MASI - Free Report) by 53.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 683,294 shares of the medical equipment provider's stock after selling 779,106 shares during the quarter. Masimo accounts for approximately 1.7% of RTW Investments LP's holdings, making the stock its 24th largest position. RTW Investments LP owned approximately 1.28% of Masimo worth $112,948,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in MASI. Smartleaf Asset Management LLC lifted its stake in Masimo by 31.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 60 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after acquiring an additional 64 shares during the last quarter. Blue Trust Inc. grew its holdings in Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after buying an additional 71 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in Masimo by 0.8% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider's stock valued at $1,622,000 after buying an additional 82 shares during the last quarter. Finally, Thrivent Financial for Lutherans lifted its position in shares of Masimo by 0.8% in the 4th quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider's stock worth $1,728,000 after acquiring an additional 83 shares during the period. Institutional investors and hedge funds own 85.96% of the company's stock.

Insider Buying and Selling

In related news, COO Bilal Muhsin sold 10,000 shares of Masimo stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $163.28, for a total transaction of $1,632,800.00. Following the completion of the transaction, the chief operating officer now owns 24,172 shares in the company, valued at approximately $3,946,804.16. This trade represents a 29.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. This trade represents a 11.02% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,053 shares of company stock worth $6,998,565. Corporate insiders own 9.70% of the company's stock.

Masimo Stock Down 0.3%

MASI stock traded down $0.49 during trading hours on Monday, reaching $155.13. 447,229 shares of the stock were exchanged, compared to its average volume of 652,814. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The company has a market cap of $8.41 billion, a price-to-earnings ratio of 106.99 and a beta of 1.23. The firm's 50-day moving average is $159.81 and its 200-day moving average is $167.57. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.12. The company had revenue of $372.00 million during the quarter, compared to analysts' expectations of $367.79 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business's quarterly revenue was down 24.5% on a year-over-year basis. During the same period last year, the business earned $0.77 EPS. On average, equities research analysts expect that Masimo Co. will post 4.1 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Raymond James lowered their target price on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a report on Thursday, April 10th. Wells Fargo & Company lowered their price target on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Piper Sandler reaffirmed an "overweight" rating and set a $200.00 price objective (down from $215.00) on shares of Masimo in a research note on Wednesday, May 7th. Finally, BTIG Research set a $193.00 price objective on Masimo and gave the stock a "buy" rating in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $191.60.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.